- NaturZen
Claims Associated with US Patent (Equizen, CanineZen)
Updated: Mar 4
The following will summarize the claims associated with the US Patent owned by Medifoods. The patent claims to be a medical treatment for disease of mammals affecting the heart, as well as functional deterioration associated with aging. Specifically, dogs, cats and horses are described. Along with that, there is claim to improving neuromuscular function, in addition to improved athletic performance. The following is the exact contents of the claims of the patent.
Description
CROSS REFERENCE TO RELATED APPLICATION
This application is a continuation-in-part of U.S. application Ser. No.
We claim:
1. A method of medical treatment of a disease, disorder or abnormal physical state in a mammal selected from the group consisting of heart disease and functional deterioration associated with ageing, the method comprising administering to a mammal an effective amount of a carrier and a nutritional supplement comprising L-Carnitine or its functional analogue, Coenzyme Q10 (Ubiquinone) or its functional analogue and Taurine or a Taurine precursor in a single or divided daily dose.
2. The method of claim 1, wherein the method comprises administering to a mammal an effective amount of a carrier and a nutritional supplement comprising L-Carnitine, Coenzyme Q10 (Ubiquinone) and Taurine or a Taurine precursor in a single or divided daily dose.
3. The method of claim 1, wherein the mammal is selected from the group consisting of a human, a dog, a cat and a horse.
4. The method of claim 1, wherein the disease, disorder or abnormal physical state comprises a disease, disorder or abnormal physical state that is due in whole or in part to aging.
5. A method of increasing neuromuscular or athletic performance in a mammal, the method comprising administering to the mammal an effective amount of a carrier and a nutritional supplement comprising L-Carnitine or its functional analogue, Coenzyme Q10 (Ubiquinone) or its functional analogue and Taurine or a Taurine precursor in a single or divided daily dose.
6. The method of claim 5, wherein the method comprises administering to the mammal an effective amount of a carrier and a nutritional supplement comprising L-Carnitine, Coenzyme Q10 (Ubiquinone) and Taurine or a Taurine precursor in a single or divided daily dose.
7. The method of claim 5, wherein the mammal is selected from the group consisting of a human, a dog, a cat and a horse.
8. The method of claim 7, wherein the mammal is a human.
9. The method of claim 2, wherein the mammal is selected from the group consisting of a human, a dog, a cat and a horse.
10. The method of claim 2, wherein the disease, disorder or abnormal physical state comprises a disease, disorder or abnormal physical state that is due in whole or in part to aging.
11. The method of claim 6, wherein the mammal is selected from the group consisting of a human, a dog, a cat and a horse.
12. The method of claim 3, wherein the mammal is a human.
13. The method of claim 9, wherein the mammal is a human.
14. The method of claim 1, wherein the disease, disorder or abnormal physical state comprises heart failure.
15. The method of claim 2, wherein the disease, disorder or abnormal physical state comprises heart failure.
The following summary of scientific citations is taken directly from the patent as well.
Cited Patent
Filing date
Publication date
Applicant
Title
Jun 7, 1995
May 6, 1997
Reliv International, Inc.
Weight loss composition for burning and reducing synthesis of fats
Aug 3, 1998
Apr 20, 1999
Advanced Micro Devices, Inc.
Gas shielding during plating
Jan 6, 1998
Oct 26, 1999
Howard; James R.
L-carnitine, acetyl-L-carnitine, and pantothenic acid or ubiquinone, combined for prevention and treatment of syndromes related to ineffective energy metabolism
May 16, 1996
Oct 26, 1999
Fuchs; Norbert
Dietetical combination preparations
* Cited by examiner
Non-Patent Citations
Reference
1
Abrahamsson, K., Eriksson, B.O., Holme, E., Jodal, U., Jonsson, A., Lindstedt, S. Pivalic Acid-Induced Carnitine Deficiency and Physical Exercise in Humans. Metabolism: Clinical & Experimental, 45 (12) : 1501-7, Dec. 1996.
2
Anand, I., Chandrashekhan, Y., De Giuli, F., Pasini, E., Mazzoletti, A., Confortini, R., Ferrari, R. Acute and Chronic Effects of Propionyl-L-Carnitine on the Hemodynamics, Exercise Capacity, and Hormones in Patients with Congestive Heart Failure. Cardiovascular Drugs & Therapy. 12 (3) : 291-9, Jul. 1998.
3
Brass, E.P., Hiatt, W.R. The Role of Carnitine and Carnitine Supplementation During Exercise in Man and in Individuals with Special Needs. Journal of the American College of Nutrition, 17 (3) : 207-15, Jun. 1998.
4
Brevetti, G., Di Lisa, F., Perna, S., Menabo, R., Barbato, R., Martone, V.D., Siliprandi, N. Carnitine-Related Alterations in Patients with Intermittent Claudication: Indication for a Focused Carnitine Therapy, Circulation, 93 (9) : 1685-9, May 1996.
5
Brevetti, G., Fanin, M., De Amicis, V., Carrozzo, R., Di Lello, F., Martone, V.D., Angelini, C. Changes in Skeletal Muscle Histology and Metabolism in Patients Undergoing Exercise Deconditioning: Effect of propionyl-L-carnitine. Muscle & Nerve, 20 (9) :1115-20, Sep. 1997.
6
Constantin-Teodosiu, D., Howell, S., Greenhaff, P.L. Carnitine Metabolism in Human Muscle Fiber Types During Submaximal Dynamic Exercise. Journal of Applied Physiology, 80 (3) :1061-4, Mar. 1996.
7
Gleim, G.G., Glace, B. Carnitine as an Ergogenic Aid in Health and Disease [editorial; comment]. Journal of the American College of Nutrition, 17 (3) : 203-4, Jun. 1998.
8
Heinonen, O.J. Carnitine and Physical Exercise. Sports Medicine, 22 (2) : 109-32, Aug. 1996.
9
Kaikkonen, J., Kosonen, L., Nyyssonen, K., Porkkala-Sarataho, E., Salonen, R., Korpela, H., Salonen, J.T. Effect of Combined Coenzyme Q10 and d-alpha-tocopheryl Acetate Supplementation on Exercise-Induced Lipid Peroxidation and Muscular Damage: A Placebo-Controlled Double-Blind Study in Marathon Runners.. Free Radical Research, 29 (1) : 85-92, Jul. 1998.
10
Lee, PJ, Harrison, EL, Jones MG, Chalmers RA, Leonard JV, Whipp BJ, "Improvement in exercise tolerance in isovaleric acidaemia with L-carnitine therapy" Journal of Inherited Metabolic Disease. 21(2):136-140, Apr. 1998.
11
Sole, M.J., Jeejeebhoy, K.N., abstract, The Failing Heart as a Starved Organ: Role of Nutrition in Heart Failure, Mar. 1998, Ottawa, Canada.
12
Sole, M.J., Keith, M., Ball, A., Kurian, R., Jeejeebhoy, K.N. Cardiovascular Pharmacology (The Failing Myocardium is Nutritionally Deficient). Journal of Cardiac Failure vol. 5 No. 3 Suppl. Sep. 1, 1999.
13
Sole, M.J., presentation slides, Heart Failure Society of America, 2nd Annual Meeting, Boca Raton, Florida, "The Fifth Paradigm: A New Look at Heart Failure", Sep. 1998.
14
Spina, RJ, Chi, MM, Hopkins MG, Nemeth, PM, Lwory, OH, Holloszy, JO, "Mitochondrial enzymes in crease in muscle in response to 7-10 days of cycle exercise.".
15
Svesson, M., Malm C., Tonkonogi, M., Ekblom, B., Sjodin, B., Sahlin, K. Effect of Q10 Supplementation on Tissue Q10 Levels and Adenine Nucleotide Catabolism During High-Intensity Exercise. International Journal of Sport Nutrition, 9 (2) : 166-80, Jun. 1990.
16
Thompson, C.H., Irish, A.B., Kemp, G.J., Taylor, D.J, Radda, G.K. The Effect of Propionyl-L-carnitine on Skeletal Muscle Metabolism in Renal Failure. Clinical Nephrology, 47 (6) :372-8, Jun. 1997.
17
Vasankari, T.J., Kujala, U.M., Vasankari, T.M., Vuorimaa, T., Ahotupa, M. Increased Serum and Low-Density-Lipoprotein Antioxidant Potential After Antioxidant Supplementation in Endurance Athletes. American Journal of Clinical Nutrition, 65 (4) :1052-6, Apr. 1997.
18
Vukovich, M.D., Sharp, R.L., Kesl, L.D., Schaulis, D.L., King D.S. Effects of a Low-Dose Amino Acid Supplement on Adaptations to Cycling Training and Untrained Individuals. International Journal of Sport Nutrition, 7 (4) : 298-309, Dec. 1997.
19
Weston, S.B., Zhou, S., Weatherby, R.P., Robson, S.J. Does Exogenous Coenzyme Q10 Affect Aerobic Capacity in Endurance Athletes?International Journal of Sport Nutrition, 7 (3) : 197-206, Sep. 1997.
Referenced by
Citing Patent
Filing date
Publication date
Applicant
Title
Jan 12, 2001
Jan 29, 2002
Lonza Ltd.
Method for enhancing or achieving training-induced bradycardia with Carnitine
Jul 11, 2000
Oct 15, 2002
N.V. Nutricia
Composition for the treatment of migraine
Dec 12, 2001
Nov 25, 2003
Herbasway Laboratories, Llc
Co-enzyme Q10 dietary supplement
Feb 20, 2001
Nov 9, 2004
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Composition for prevention and/or treatment of vascular diseases, comprising propionyl L-carnitine and coenzyme Q10
Mar 3, 2004
Jan 30, 2007
Ronald G. Udell
Solubilized CoQ-10 and carnitine
Aug 18, 2005
Sep 25, 2007
Soft Gel Technologies, Inc.
Solubilized CoQ-10 and carnitine
Nov 12, 2004
Mar 18, 2008
Ssv Therapeutics, Inc.
Carnitine conjugates as dual prodrugs and uses thereof
Sep 24, 2007
May 11, 2010
Soft Gel Technologies, Inc.
Solubilized CoQ-10 and carnitine
Aug 11, 2006
Aug 17, 2010
Ssv Therapeutics, Inc.
Production of carnitine conjugate intermediates
Sep 29, 2004
Jan 31, 2012
Soft Gel Technologies, Inc.
Solubilized CoQ-10
Sep 29, 2003
Feb 28, 2012
Soft Gel Technologies, Inc.
Solubilized CoQ-10
Sep 9, 2005
Apr 3, 2012
Soft Gel Technologies, Inc.
Method of making a soft gel capsule comprising CoQ-10 solubilized in a monoterpene
Dec 30, 2005
Apr 3, 2012
Hill'S Pet Nutrition, Inc.
Methods for enhancing the quality of life of a senior animal
Jul 18, 2008
Aug 28, 2012
Hill'S Pet Nutrition, Inc.
Methods for enhancing the quality of life of a senior animal
Mar 14, 2008
Jan 1, 2013
Soft Gel Technologies, Inc.
Ubiquinol and alpha lipoic acid compositions
Dec 23, 2010
Jun 30, 2011
Hill'S Pet Nutrition, Inc.
Composition and method
Dec 2, 2008
Jun 11, 2009
Cpc (Tianjin) Fine Chemicals Co., Ltd.
Compositions comprising coenzyme q-10 and garlic oil for an increased coenzyme q-10 bioavailability
Dec 2, 2008
Jun 11, 2009
Cpc (Tianjin) Fine Chemicals Co., Ltd.
Compositions comprising coenzyme q-io and garlic oil for an increased coenzyme q-10 bioavailability
Mar 12, 2010
Sep 16, 2010
Viridis Biopharma Pvt Ltd,
Method of use of vitamin k as energy enhancer in diverse disease states
* Cited by examiner
Classifications
U.S. Classification
International Classification
Cooperative Classification
A23L1/296, A23L1/29, A23V2002/00, A61K31/205
European Classification
A61K31/205, A23L1/29, A23L1/29F
Rotate
Original Image
Google Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send Feedback
Data provided by IFI CLAIMS
